This interdisciplinary meeting focuses on the question of which factors impact risk perceptions regarding vaccination decisions in the specific context of the Internet. Moreover, it will discuss how risks and risk negations should be communicated on the Internet.
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.
This study establishes whether the immunisation with hexavalent vaccines increased the short term risk of sudden unexpected deaths (SUD) in infants in Italy, following the signal of an association between vaccination in the second year of life with a hexavalent vaccine and SUD in the two days following vaccination reported in Germany in 2003.
ECDC Director Marc Sprenger and WHO/Europe Regional Director Zsuzsanna Jakab have signed an Administrative Agreement between ECDC and WHO/Europe during the 8th Senior Officials Meeting of the European Commission (EC) and World Health Organisation (WHO), held in Brussels on 24-25 March 2011.
Vaccination helps to prevent diseases and, above all, saves lives. This was the message at an expert meeting on childhood immunisation organised by the Hungarian Presidency. ECDC Director Marc Sprenger stressed the importance of successful vaccination programmes across Europe and future challenges.
In the context of an active nationwide surveillance network, this study describes pneumoccocal meningitis in children aged from 1 day to 15 years during a 8 year study period (2001-2008) in France. 951 pneumoccocal meningitis cases were reported among 3312 children with bacterial meningitis. T